

Detailed Action

Claims 5, 8, 10-12, 18, 20 and 32-35 remain pending in the application.

Applicant's representative was contacted on March 08, 2011 to amend independent claims 5 and 18, and to cancel claims 32-35

Authorization for the examiner's amendment was given in a telephone interview with Jeremy Jay, on March 19, 2011.

With respect to the proposed claims, an examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it must be submitted no later than the payment of the issue fee.

EXAMINER'S AMENDMENT

In the claims

Correct claims 5 and 18 as follows:

Page 2, lines 7-12 of **claim 5**, the phrase "or (ii) a variant of the amino acid sequence of SEQ ID NO: 1, wherein the variant comprises the amino acid sequence of SEQ ID NO: 1 except for 1-5 amino acid substitutions, deletions, or additions, and wherein the variant retains the ability to bind to the IL-21 receptor and produce a physiological effect produced by binding of the IL-21 polypeptide comprising the amino acid sequence of SEQ ID NO: 1 to the IL-21 receptor" has been deleted.

Change(s) applied
to document,

/B.S.H./
5/11/2011

Page 3, lines ⁸7-12 of **claim 18**, the phrase "or (ii) a variant of the amino acid sequence of SEQ ID NO: 1, wherein the variant comprises the amino acid sequence of SEQ ID NO: 1 except for 1-5 amino acid substitutions, deletions, or additions, and wherein the variant retains the ability to bind to the IL-21 receptor and produce a physiological effect produced by binding of